RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

RO.CH

325.6

+0.74%↑

NOVN.CH

113.89

+0.11%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Elenco Azioni・Lonza Group AG

Lonza Group AG

Chiusa

SettoreSettore sanitario

493.4 3.09

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

478.65

Massimo

494.2

Metriche Chiave
By Trading Economics
Entrata	57M 483M
Vendite	-621M 3B
P/E Media del settore	37.585 67.147
Rendimento da dividendi	1.04
Margine di Profitto	16.345
Dipendenti	20,000
EBITDA	-181M 822M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+37.73% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	1.04% 2.36%
Utili prossimi	22 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-4.6B 34B
Apertura precedente	490.31
Chiusura precedente	493.4

Notizie sul Sentiment di mercato

By Acuity

14%

86%

24 / 347 Classifica in Healthcare

Lonza Group AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mar 2026, 17:44 UTC

Acquisizioni, Fusioni, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28 gen 2026, 06:15 UTC

Utili

Lonza Sales Grow on New Contract Momentum

23 lug 2025, 08:30 UTC

Utili

I principali Market Mover

Lonza Shares Rise After Outlook Lift for Core Business

9 mar 2026, 10:34 UTC

Discorsi di Mercato

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6 mar 2026, 17:12 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6 mar 2026, 17:10 UTC

Acquisizioni, Fusioni, Takeovers

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6 mar 2026, 17:09 UTC

Acquisizioni, Fusioni, Takeovers

Lonza to Retain 40% Stake in CHI

6 mar 2026, 17:08 UTC

Acquisizioni, Fusioni, Takeovers

Lonza Will Receive Upfront Proceeds of CHF1.7B

6 mar 2026, 17:07 UTC

Acquisizioni, Fusioni, Takeovers

Lonza: Transaction Expected to Close in 2H

6 mar 2026, 17:07 UTC

Acquisizioni, Fusioni, Takeovers

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6 mar 2026, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28 gen 2026, 12:04 UTC

Discorsi di Mercato

Utili

Lonza Results Show a Company in Good Shape -- Market Talk

28 gen 2026, 05:35 UTC

Utili

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28 gen 2026, 05:34 UTC

Utili

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28 gen 2026, 05:33 UTC

Utili

Lonza Issues 2026 View

28 gen 2026, 05:32 UTC

Utili

Lonza 2025 Core Ebitda Margin 31.6%

28 gen 2026, 05:32 UTC

Utili

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28 gen 2026, 05:32 UTC

Utili

Lonza 2025 Core Ebitda CHF2.06B

28 gen 2026, 05:30 UTC

Utili

Analysts Saw Lonza 2025 Sales at CHF7.54B

28 gen 2026, 05:30 UTC

Utili

Lonza 2025 Sales CHF6.53B

27 ott 2025, 08:24 UTC

Discorsi di Mercato

Lonza on Track to Meet Long-Term Goals -- Market Talk

23 ott 2025, 10:53 UTC

Discorsi di Mercato

Utili

Lonza Set to Recover as Contracts Flow in -- Market Talk

23 lug 2025, 08:00 UTC

Discorsi di Mercato

Utili

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 lug 2025, 04:44 UTC

Utili

Lonza 1H Sales Grew 19% at Constant Currency

23 lug 2025, 04:43 UTC

Utili

Lonza 1H Core Ebitda Margin 29.6%

23 lug 2025, 04:43 UTC

Utili

Lonza: Margins Will Be Only Minimally Affected

23 lug 2025, 04:42 UTC

Utili

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 lug 2025, 04:42 UTC

Utili

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 lug 2025, 04:38 UTC

Utili

Lonza 1H Net Pft CHF426M

23 lug 2025, 04:37 UTC

Utili

Lonza Backs 2025 View for CHI Business

Confronto tra pari

Modifica del prezzo

Lonza Group AG Previsione

Obiettivo di Prezzo

By TipRanks

37.73% in crescita

Previsioni per 12 mesi

Media 660 CHF 37.73%

Alto 670 CHF

Basso 630 CHF

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lonza Group AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Lonza Group AG - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

24 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.